Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dyadic International (DYAI)

Dyadic International (DYAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,778
  • Shares Outstanding, K 36,188
  • Annual Sales, $ 3,500 K
  • Annual Income, $ -5,810 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.29
  • Price/Sales 14.59
  • Price/Cash Flow N/A
  • Price/Book 10.55
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.24
  • Most Recent Earnings $-0.06 on 11/12/25
  • Next Earnings Date 03/25/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 375.17% (-279.44%)
  • Historical Volatility 46.68%
  • IV Percentile 55%
  • IV Rank 21.82%
  • IV High 1,199.56% on 02/12/26
  • IV Low 145.10% on 09/08/25
  • Expected Move (DTE 10) 0.0425 (5.31%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 3
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 758
  • Open Int (30-Day) 802
  • Expected Range 0.7575 to 0.8425

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.03
  • Number of Estimates 1
  • High Estimate -0.03
  • Low Estimate -0.03
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7429 +7.69%
on 03/02/26
0.8989 -11.00%
on 02/13/26
-0.0330 (-3.96%)
since 02/09/26
3-Month
0.7429 +7.69%
on 03/02/26
1.0400 -23.08%
on 12/19/25
-0.2000 (-20.00%)
since 12/09/25
52-Week
0.7110 +12.52%
on 08/15/25
1.5500 -48.39%
on 03/14/25
-0.6500 (-44.83%)
since 03/07/25

Most Recent Stories

More News
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...

DYAI : 0.8000 (+4.22%)
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

JUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...

DYAI : 0.8000 (+4.22%)
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...

DYAI : 0.8000 (+4.22%)
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets

JUPITER, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing...

DYAI : 0.8000 (+4.22%)
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins

JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI) , a global biotechnology company producing precision-engineered, animal-free proteins and enzymes...

DYAI : 0.8000 (+4.22%)
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

RALEIGH, NC / ACCESS Newswire / December 8, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and...

MOB : 5.82 (+2.11%)
BOSC : 4.85 (+2.54%)
STRT : 78.71 (-2.16%)
ELWT : 6.72 (-6.01%)
FLUX : 1.4700 (+7.30%)
DGX.VN : 3.790 (+5.28%)
BCHT.TO : 3.13 (-1.57%)
GAME : 0.2978 (+3.15%)
WYY : 4.49 (-3.02%)
ACNT : 13.21 (-0.38%)
DCGO : 0.6722 (+0.04%)
VELO : 12.21 (+0.83%)
Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets

JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free proteins...

DYAI : 0.8000 (+4.22%)
iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

RALEIGH, NC / ACCESS Newswire / December 1, 2025 / iAccess Alpha's Virtual Best Ideas Winter Investment Conference will take place on December 9-10, 2025, bringing together top micro-cap companies and...

MOB : 5.82 (+2.11%)
BOSC : 4.85 (+2.54%)
STRT : 78.71 (-2.16%)
ELWT : 6.72 (-6.01%)
DGX.VN : 3.790 (+5.28%)
BCHT.TO : 3.13 (-1.57%)
GAME : 0.2978 (+3.15%)
ACNT : 13.21 (-0.38%)
WYY : 4.49 (-3.02%)
DCGO : 0.6722 (+0.04%)
DGXX : 2.73 (+0.37%)
SCNX : 0.3893 (-1.74%)
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

Completed strategic pivot from R&D focus to commercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relations...

DYAI : 0.8000 (+4.22%)
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered,...

DYAI : 0.8000 (+4.22%)

Business Summary

Dyadic International, Inc. is a leading genomics company with the groundbreaking technology that brings nature to the marketplace. Dyadic is poised to become a global leader in proteomics through the discovery, development, and manufacturing of novel products derived from the DNA of complex living organisms...

See More

Key Turning Points

3rd Resistance Point 0.9138
2nd Resistance Point 0.8719
1st Resistance Point 0.8359
Last Price 0.8000
1st Support Level 0.7580
2nd Support Level 0.7161
3rd Support Level 0.6801

See More

52-Week High 1.5500
Fibonacci 61.8% 1.2295
Fibonacci 50% 1.1305
Fibonacci 38.2% 1.0315
Last Price 0.8000
52-Week Low 0.7110

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar